Gapping down
In reaction to earnings/guidance:
- DCT -15.8%, SGH -14.2% (also to acquire Stratus Technologies), RH -9.2% (lowers FY22 revenue and op mgn guidance; maintains Q2 guidance), UHS -7.7%, FIZZ -4.3%, WBA -2.4%, STZ -0.7%
Other news:
- HYPR -18.5% (CEO will step down for personal reasons)
- CYTK -16.9% (proposes $450 mln convertible notes offering)
- MSTR -8.2% (EU says provisional agreement reached on transparency of crypto asset transfers)
- BITO -5.8% (EU says provisional agreement reached on transparency of crypto asset transfers)
- THC -5.5% (in sympathy with weak UHS guidance)
- COIN -5.1% (EU says provisional agreement reached on transparency of crypto asset transfers)
- WSM -4.8% (in sympathy with weak RH guidance)
- W -4.8% (in sympathy with weak RH guidance)
- HCA -4% (in sympathy with weak UHS guidance)
- CYH -3.8% (in sympathy with weak UHS guidance)
- UBS -3.3% (ordered to pay $25 mln to settle SEC fraud charges, according to Reuters)
- AADI -3.2% (receives notice from EOC Pharma of termination of License Agreement )
- HPK -3% (stock offering)
- LXRX -2.2% (announces positive top-line results from phase 2 study of LX9211)
- RKLB -2.2% (Lunar Photon spacecraft successfully completes the third of seven planned orbit raising maneuvers)
- OIS -1.8% (settles dispute with HCperf Holdings)
- BA -1.8% (Inspector General sends letter to FAA regarding oversight of 737 Max issues)
- WBD -1.6% (NXST nearing a deal to acquire majority control of the CW Network from WBD and PARA, according to WSJ)
- BGNE -1.4% (Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma)
- BILI -1.4% (shareholders approve proposed conversion to primary listing on the Hong Kong Stock Exchange; Proposed Conversion is expected to be October 3, 2022)
- XRX -1.2% (CEO and Vice Chairman John Visentin unexpectedly passes away)
Analyst comments:
- DUK -1.3% (downgraded to Neutral from Buy at UBS)